Peer-reviewed veterinary case report
Treatment options for resistant multicentric lymphoma in dogs
By Kelley Zimmerman et al.·Published in Veterinary and Comparative Oncology·2023·View original on Semantic Scholar →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of mechlorethamine, vinblastine, procarbazine, and prednisone for the treatment of resistant multicentric canine lymphoma.
- Species:
- dog
Plain-English summary
A group of 36 dogs with relapsed multicentric lymphoma (a type of cancer affecting lymph nodes) were treated with a modified chemotherapy protocol that replaced vincristine with vinblastine to see if it would be less toxic. While only 25% of the dogs responded well to the treatment, they experienced minimal side effects and did not need to be hospitalized. The dogs had a median survival time of 45 days after starting the treatment. This approach showed some benefit without the severe gastrointestinal issues often seen with other chemotherapy drugs, suggesting that increasing the dose might improve results in the future.
People also search for: dog lymphoma treatment options · vinblastine for dogs cancer · canine lymphoma survival rate
Abstract
Multi-agent chemotherapy successfully induces remission in most naïve, high-grade canine lymphoma patients; however, disease recurrence is common. MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) is an effective rescue protocol used to re-induce remission, but is associated with gastrointestinal toxicity and can be a less desirable option for patients that previously failed vincristine-containing protocols. Therefore, alternative members of the vinca alkaloid family, such as vinblastine, could be potentially advantageous as substitutes for vincristine to reduce gastrointestinal toxicity and chemoresistance. The objective of this study was to report the clinical outcomes and toxicity of 36 dogs with relapsed or refractory multicentric lymphoma treated with a modified MOPP protocol whereby vincristine was replaced with vinblastine (MVPP). The overall response rate to MVPP was 25% with a median progression free survival of 15 days and a median overall survival of 45 days. MVPP at the prescribed doses resulted in modest and transient clinical benefit, but was well tolerated with no treatment delays or hospitalizations secondary to side effects. Given the minimal toxicity, dose intensification could be considered to improve clinical responses.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Semantic Scholar: https://www.semanticscholar.org/paper/37222086